Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response

被引:20
|
作者
Wu, Jiani [1 ]
Zeng, Dongqiang [1 ]
Zhi, Shimeng [1 ]
Ye, Zilan [1 ]
Qiu, Wenjun [1 ]
Huang, Na [1 ]
Sun, Li [1 ]
Wang, Chunlin [1 ]
Wu, Zhenzhen [1 ]
Bin, Jianping [2 ]
Liao, Yulin [2 ]
Shi, Min [1 ]
Liao, Wangjun [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Nanfang Hosp, Dept Cardiol, State Key Lab Organ Failure Res, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Tumor-derived exosome; Single-cell analysis; Biomarker; Immunotherapy; Tumor microenvironment; CANCER EXOSOMES; EGFR MUTATIONS; LUNG-CANCER; VESICLES; GENE;
D O I
10.1186/s12967-021-03053-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Tumor-derived exosomes (TEXs) are involved in tumor progression and the immune modulation process and mediate intercellular communication in the tumor microenvironment. Although exosomes are considered promising liquid biomarkers for disease diagnosis, it is difficult to discriminate TEXs and to develop TEX-based predictive biomarkers. Methods In this study, the gene expression profiles and clinical information were collected from The Cancer Genome Atlas (TCGA) database, IMvigor210 cohorts, and six independent Gene Expression Omnibus datasets. A TEXs-associated signature named TEXscore was established to predict overall survival in multiple cancer types and in patients undergoing immune checkpoint blockade therapies. Results Based on exosome-associated genes, we first constructed a tumor-derived exosome signature named TEXscore using a principal component analysis algorithm. In single-cell RNA-sequencing data analysis, ascending TEXscore was associated with disease progression and poor clinical outcomes. In the TCGA Pan-Cancer cohort, TEXscore was elevated in tumor samples rather than in normal tissues, thereby serving as a reliable biomarker to distinguish cancer from non-cancer sources. Moreover, high TEXscore was associated with shorter overall survival across 12 cancer types. TEXscore showed great potential in predicting immunotherapy response in melanoma, urothelial cancer, and renal cancer. The immunosuppressive microenvironment characterized by macrophages, cancer-associated fibroblasts, and myeloid-derived suppressor cells was associated with high TEXscore in the TCGA and immunotherapy cohorts. Besides, TEXscore-associated miRNAs and gene mutations were also identified. Further experimental research will facilitate the extending of TEXscore in tumor-associated exosomes. Conclusions TEXscore capturing tumor-derived exosome features might be a robust biomarker for prognosis and treatment responses in independent cohorts.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
    Song, Peng
    Li, Yuan
    Zhang, Moyan
    Lyu, Baihan
    Cui, Yong
    Gao, Shugeng
    JOURNAL OF IMMUNOTHERAPY, 2025, 48 (01) : 6 - 17
  • [42] Single-cell spatial transcriptomics unravels cell states and ecosystems associated with clinical response to immunotherapy
    Abdulrahman, Ziena
    Slieker, Roderick C.
    Mcguire, Daniel
    Welters, Marij J. P.
    van Poelgeest, Mariette I. E.
    van der Burg, Sjoerd H.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [43] A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing
    Xu Chen
    Chuang Peng
    Yu Chen
    Bai Ding
    Sulai Liu
    Yinghui Song
    Yuhang Li
    Bo Sun
    Ranzhiqiang Yang
    BMC Bioinformatics, 24
  • [44] A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing
    Chen, Xu
    Peng, Chuang
    Chen, Yu
    Ding, Bai
    Liu, Sulai
    Song, Yinghui
    Li, Yuhang
    Sun, Bo
    Yang, Ranzhiqiang
    BMC BIOINFORMATICS, 2023, 24 (01)
  • [45] Dissecting the role of cancer-associated fibroblast-derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single-cell transcriptomic study
    Zheng, Shaoquan
    Liang, Jie-Ying
    Tang, Yuhui
    Xie, Jindong
    Zou, Yutian
    Yang, Anli
    Shao, Nan
    Kuang, Xiaying
    Ji, Fei
    Liu, Xuefeng
    Tian, Wenwen
    Xiao, Weikai
    Lin, Ying
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (02):
  • [46] Single-cell sequencing analysis related to sphingolipid metabolism guides immunotherapy and prognosis of skin cutaneous melanoma
    Ding, Yantao
    Zhao, Zhijie
    Cai, Huabao
    Zhou, Yi
    Chen, He
    Bai, Yun
    Liu, Zhenran
    Liu, Shengxiu
    Zhou, Wenming
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics
    Liu, Wendi
    Puri, Anusha
    Fu, Doris
    Chen, Lee
    Wang, Cassia
    Kellis, Manolis
    Yang, Jiekun
    CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (04) : 313 - 332
  • [48] CD47 is a tumor cell-derived exosomal signature and regulates tumor immune microenvironment and immunotherapy responses
    Luan, Yifei
    Zhang, Yinghui
    Li, Shangjin
    Gao, Caiyun
    Ying, Xinyi
    Zhao, Shaojie
    Zhang, Bing
    TRANSLATIONAL ONCOLOGY, 2025, 53
  • [49] Integrating TCGA and Single-Cell Sequencing Data for Hepatocellular Carcinoma: A Novel Glycosylation (GLY)/Tumor Microenvironment (TME) Classifier to Predict Prognosis and Immunotherapy Response
    Wu, Yun
    Chen, Jiaru
    Zhu, Riting
    Huang, Guoliang
    Zeng, Jincheng
    Yu, Hongbing
    He, Zhiwei
    Han, Cuifang
    METABOLITES, 2024, 14 (01)
  • [50] Single-cell sequencing reveals the role of aggrephagy-related patterns in tumor microenvironment, prognosis and immunotherapy in endometrial cancer
    Yuan, Yuquan
    Ren, Chunyan
    Shu, Jin
    Zhu, Keyang
    Li, Ganghui
    Liu, Bao
    Huang, Jianrong
    Huang, Yinde
    Zhao, Chengzhi
    FRONTIERS IN ONCOLOGY, 2025, 15